In clinical practice, FVIII concentrate dosing is still mainly based on bodyweight.1 As overweight and obesity are a growing global health problem with a current prevalence of 43.3% in the adult European and North American haemophilia population, appropriate dosing strategies for replacement therapy in this patient group are relevant to safeguard treatment costs without loss of quality of care.2 Here, F8 is linked to hemophilia.